Clinical trials: Latent Tuberculosis
Latent Tuberculosis Infection, Tuberculosis
Diagnosis of Tuberculosis Infection in HIV Co-infected Children
Background: The TB and HIV epidemics are closely linked in developing countries, where 450,000 children die from HIV annually. TB is a major cause of death in HIV-infected children and is reversing gains made in child survival.
- Conditions
- Latent Tuberculosis Infection, Tuberculosis, HIV Infections
- Trial name
- ThrasherIGRA (NCT00541294)
- Where
- South Africa
- Volunteers
- 250 people
- Sponsor
- Case Western Reserve University
Close Contacts of Active Tuberculosis
Efficacy of Nyaditum Resae(R) Against Active TB in Georgia
The use of a supplement food like "Nyaditum resae" is a reliable opportunity to stop the progression towards active TB through the most updated knowledge of this disease:the induction of tolerance.
- Trial name
- NCT02897180
- Testing
- Nyaditum resae(R)
- Where
- Georgia
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Tuberculosis Infection
Evaluating Diagnostics for Paediatric Tuberculosis by Blood Culture
Detection of M. tuberculosis in clinical specimens of children has a low sensitivity because specimens are either difficult to collect or contain low levels of M. tuberculosis.
- Trial name
- NCT01434758
- Where
- Vietnam
- Volunteers
- 560 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Tuberculosis Infection, Tuberculosis
BCG Revaccination in Children and Adolescents
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection.
- Trial name
- BRiC (NCT05330884)
- Testing
- BCG vaccine, Oral Chemoprophylaxis
- Where
- India
- Volunteers
- 9,200 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Tuberculosis
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB).
- Trial name
- NCT07124559
- Testing
- Rifapentine, Isoniazid, Dolutegravir
- Where
- 11 sites in Botswana, Haiti and 4 more
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis
GXT - GeneXpert or Chest-X-ray or Tuberculin Skin Testing for Household Contact Assessment
The objective of the study is to compare outcomes from three different strategies for the management of household (HH) contacts of individuals with newly diagnosed microbiologically confirmed active pulmonary TB.
- Trial name
- NCT04528823
- Testing
- Strategy 2: Symptom screen, Genexpert and TST, Strategy 3:Symptom screen, CXR but NO TST
- Where
- 4 sites in Benin, Brazil
- Volunteers
- 1,589 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Tuberculosis
Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison
LTBI Treatment is effective in prison
- Trial name
- LTBI_prison (NCT00767975)
- Testing
- isoniazid , randomized, open label, rifampin, randomized, open label
- Where
- Taiwan
- Volunteers
- 2,384 people
- Sponsor
- National Taiwan University Hospital
Tuberculosis
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month…
- Trial name
- PREVENT TB (NCT00023452)
- Testing
- RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 8,053 people
- Sponsor
- Centers for Disease Control and Prevention
Active Tuberculosis, Latent Tuberculosis Infection
Performance Evaluation of the VIDAS TB-IGRA Assay.
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection.
- Conditions
- Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
- Trial name
- NCT04048018
- Testing
- Blood draw and IGRA test
- Where
- 24 sites in United States, Brazil and 7 more
- Volunteers
- 2,401 people, healthy volunteers welcome
- Sponsor
- BioMérieux
Tuberculosis Infection, Household Contacts
Window Prophylaxis for Pediatric Tuberculosis Prevention Trial
The goal of this cluster-randomized controlled trial is to evaluate the effectiveness of tuberculosis preventive treatment (TPT) administered during the "window period" to prevent new Mycobacterium tuberculosis infections in…
- Conditions
- Tuberculosis Infection, Household Contacts, Children, Adolescent
- Trial name
- TB-WIN (NCT07086820)
- Testing
- Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks, Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks
- Where
- 13 sites in Chile
- Volunteers
- 647 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Tuberculosis
Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection
This is a doble-blind, masked, compared with placebo clinical trial in pediatric population in contact with tuberculosis with or without tuberculosis infection.
- Trial name
- NCT02581579
- Testing
- Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
- Where
- 3 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Manresana de Micobacteriologia, SL
Rheumatic Disease, Rheumatoid Arthritis
The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection
The purposes of this study 1. to compare the positivity of tuberculin skin test(TST) and QuantiFERON-TB Gold (QFT-G), and determine the level of agreement between two tests in patients with rheumatic diseases 2.
- Conditions
- Rheumatic Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Tuberculosis
- Trial name
- NCT01685905
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Hanyang University
Tuberculosis, Latent
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or…
- Trial name
- BREACH-TB (NCT06568484)
- Testing
- Bedaquiline, Isoniazid, rifapentine, Levofloxacin
- Where
- 8 sites in Mongolia, Peru and 2 more
- Volunteers
- 2,530 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Pulmonary, Interferon-gamma Release Tests
IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection
The aim of this project is to analyze the potential contribution of IGRA test QuantiFERON-TB Gold In Tube test (QTF-GIT, Cellestis Limited, Carnegie, Victoria, Australia) in the diagnosis of tuberculosis (TB - active or latent)…
- Conditions
- Tuberculosis, Pulmonary, Interferon-gamma Release Tests, Tuberculin Test
- Trial name
- TBTubercolar (NCT02653404)
- Testing
- IGRA test (QTF-GIT)
- Where
- 3 sites in Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Siena
Cystic Fibrosis, Hepatitis A
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization…
- Conditions
- Cystic Fibrosis, Hepatitis A, Hepatitis B, Tuberculosis
- Trial name
- NCT02605538
- Testing
- Vaccination with vaccine against hepatitis A and B
- Where
- Sweden
- Volunteers
- healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Tuberculosis
Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection
The objective of the study was to compare the compliance and the side effects of a short course to treatment of latent tuberculosis infection during 3 months(isoniazid plus rifampin)group I, with the standard course for 6…
- Trial name
- NCT00397709
- Testing
- I ( isoniazid), II (isoniazid + rifampin )
- Where
- Spain
- Volunteers
- 228 people
- Sponsor
- Hospital Virgen de la Luz
TB - Tuberculosis
Start4All SCREEN-TB PROTOCOL
Tuberculosis (TB) remains the leading cause of death from a single infectious agent globally, with millions of people still undiagnosed or diagnosed late.
- Trial name
- SCREEN-TB (NCT07517471)
- Testing
- Near point of care (NPOC) NAATs, Low-complexity nucleic acid amplification tests (LC-NAATs), LC-NAAT using pooled testing
- Volunteers
- 37,000 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Tuberculosis, HIV
Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)
Single-arm, multi-center, Phase I/II clinical trial, in two groups. Individuals with HIV infection taking Efavirenz (EFV), nevirapine (NVP) or lopinavir/ritonavir (LPV/r) and two nucleoside reverse transcriptase inhibitors (NRTI)…
- Trial name
- DOLPHIN KIDS (NCT05122767)
- Testing
- Dolutegravir, 3HP
- Where
- 2 sites in South Africa
- Volunteers
- 92 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis
TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
Compared to adults, children appear to require higher weight-based doses of rifapentine to acheive comparable drug levels. TBTC Study 26, a study of the effectiveness and tolerability of weekly rifapentine/isoniazid for three…
- Trial name
- NCT00164450
- Testing
- Isoniazid, Rifapentine
- Where
- 24 sites in United States, Brazil and 2 more
- Volunteers
- 158 people
- Sponsor
- Centers for Disease Control and Prevention
Latent Tuberculosis Infection
Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
Background: Tuberculosis (TB) remains the most important infectious disease in the world. Keys to successful control of TB is rapid diagnosis, prompt treatment, as well as effective preventive therapy for contacts with latent TB…
- Trial name
- NCT02208427
- Testing
- Rifapentine and Isoniazid for 3 months, Isoniazid for 9 months
- Where
- Taiwan
- Volunteers
- 283 people
- Sponsor
- National Taiwan University Hospital